-=MacroGenics (MGNX) reported earnings on Tue 5 May 20 (a/h)

MacroGenics (MGNX) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $0.99 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 9.90%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.71 per share when it actually produced a loss of $0.62, delivering a surprise of 12.68%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

MacroGenics, which belongs to the Zacks Medical - Products industry, posted revenues of $13.68 million for the quarter ended March 2020, surpassing the Zacks Consensus Estimate by 84.12%. This compares to year-ago revenues of $9.66 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

MacroGenics shares have lost about 34.3% since the beginning of the year versus the S&P 500's decline of -12%.